

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-77 (cancelled)

78. (currently amended) A method of administering a biologically active protein which ~~does not therapeutically alter blood glucose levels~~ is not insulin to a subject, said method comprising topically applying to the skin or epithelium of the subject the protein in conjunction with an effective amount of a positively charged carrier, said positively charged carrier comprising a positively charged backbone having attached positively charged branching groups, wherein the association between the carrier and the biologically active protein is non-covalent.
79. (currently amended) [[A]]The method according to claim 78 wherein the composition provides greater transdermal delivery of the biologically active protein relative to the agent in the absence of the carrier.
80. (currently amended) [[A]]The method according to claim 79 in which the biologically active protein has therapeutic activity.

Claims 81-83 (cancelled)

84. (currently amended) [[A]]The method according to claim 80 in which the biologically active protein and carrier are administered to the subject in a composition containing both components.

85. (currently amended) [[A]]The method according to claim 80 in which the biologically active protein and carrier are administered separately to the subject.

Claims 86-87 (cancelled)

88. (currently amended) [[A]]The method according to claim 80 in which the composition is a controlled release composition or sustained release composition.

89. (cancelled)

90. (currently amended) [[A]]The method according to claim 80 in which the therapeutic protein is a botulinum toxin.

91. (currently amended) [[A]]The method according to claim 90 in which the botulinum toxin is selected from botulinum toxin serotypes A, B, C, D, E, F and G.

92. (currently amended) [[A]]The method according to claim 90 in which the botulinum toxin comprises a botulinum toxin derivative.

93. (currently amended) [[A]]The method according to claim 90 in which the botulinum toxin comprises a recombinant botulinum toxin.
94. (currently amended) [[A]]The method according to claim 90 in which the botulinum toxin is administered to provide an aesthetic and/or cosmetic benefit to the subject.
95. (currently amended) [[A]]The method according to claim 90 in which the botulinum toxin is administered to the subject for prevention or reduction of symptoms associated with muscle spasm or cramping.
96. (currently amended) [[A]]The method according to claim 90 in which the botulinum toxin and the positively charged carrier are administered topically to a site on the face of the subject.
97. (currently amended) [[A]]The method according to claim 90 in which the botulinum toxin and the positively charged carrier are administered topically to a site on the subject other than the face.

Claims 98 - 240 (cancelled)